COH04S1

COH04S1
Vaccine description
TargetSARS-CoV-2
Vaccine typeViral vector
Clinical data
Routes of
administration
Intramuscular
Identifiers
CAS Number

COH04S1 is a covid vaccine developed by the City of Hope Medical Center. This vaccine targets patients who are immunocompromised; immunocompromised patients have often shown a weak antibody response to past COVID-19 vaccines. COH04S1 is also targeted on people who are at a high risk of COVID-19 complications. The City of Hope Medical Center strives to make a better option than the current EUA and FDA approved vaccines, which are not working as well on this group of individuals.

The group leading the investigation of the vaccine is led by scientists named Felix Wussow with a Ph.D., Flavia Chiuppesi with a Ph.D. as well, them both City of Hope assistant research professors in the Department of Hematology & Hematopoietic Cell Transplantation. The leader is named Don J. Diamond, Ph.D.: professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope. The vaccine is the first to study the safety and effectiveness in patients that have received a bone marrow transplant or chimeric antigen receptor therapy. It is also the first to look at the differences between the Pfizer vaccine with one that accommodates people who are receiving immunosuppressive therapy.

Previous COVID-19 vaccines in blood cancer patients show a high probability that 1 out of 4 blood cancer patients fail to produce antibodies. COH04S1 hopes to lower the chances of failure in producing antibodies in blood cancer patients.

This vaccine is built on a FDA-approved platform known as modified vaccinia ankara, also known as MVA. This platform has famously been used safely worldwide and effectively in cancer and transplant patients.

  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).